BIO017 for Angelman Syndrome Granted Orphan Drug Status
In a recent press release, clinical stage biotech and biopharmaceutical company Biom Therapeutics (“Biom”) shared that its drug candidate BIO017 was granted Orphan Drug designation.
In a recent press release, clinical stage biotech and biopharmaceutical company Biom Therapeutics (“Biom”) shared that its drug candidate BIO017 was granted Orphan Drug designation.
At the very end of March 2021, specialty pharmaceuticals company JCR Pharmaceuticals Co., Ltd. (“JCR”) shared that its investigational drug candidate JR-171 received Orphan Drug
Cancer Network recently reported that Jazz Pharmaceuticals’ Vyxeos was approved by the FDA to treat therapy-related pediatric patients one year or older who were
As Parkinson’s diseases slowly erodes a person’s control of their movement, many normal parts of life become much more difficult. In a new study
A reader named Fiorella, recently reached out in response to an article we wrote entitled: A Common Parasite With An Uncommon Name: Toxoplasma Gondii is
Researchers from the University of Barcelona have recently found a new biomarker which may be able to diagnose Parkinson’s disease sooner. This biomarker is a
SIGN UP FOR OUR NEWSLETTER | |
|
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
What best describes you when it comes to rare disease? (check all that apply)
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.